Takeda Pharmaceutical (TAK) Revenue (2017 - 2026)

Takeda Pharmaceutical's Revenue history runs 10 years deep, the most recent figure standing at $7.0 billion for Q1 2026.

• In Q1 2026, Revenue fell 11.85% year-over-year to $7.0 billion; the TTM figure through Mar 2026 stood at $46.2 billion (changed 0.18% YoY), while the FY2026 annual figure was $29.9 billion, changed 0.48% from the prior year.
• Revenue was $7.0 billion for Q1 2026 at Takeda Pharmaceutical, down from $7.1 billion in the prior quarter.
• In the past five years, Revenue ranged from a high of $23.9 billion in Q3 2025 to a low of $6.9 billion in Q4 2024.
• Historically, Revenue has averaged $9.5 billion across 5 years, with a median of $7.7 billion in 2023.
• The sharpest annual moves came in 2022 and 2024: Revenue slipped 13.32% in 2022, then jumped 207.41% in 2024.
• A 5-year view of Revenue shows it stood at $7.8 billion in 2022, then declined by 8.4% to $7.1 billion in 2023, then fell by 2.7% to $6.9 billion in 2024, then increased by 2.81% to $7.1 billion in 2025, then retreated by 1.86% to $7.0 billion in 2026.
• The last three Revenue figures came in at $7.0 billion (Q1 2026), $7.1 billion (Q4 2025), and $23.9 billion (Q3 2025), per Business Quant data.